SCHEMBL1966149

SCHEMBL1966149

CCOC(=O)c1cc([N+](=O)[O-])c(NC(C)=O)cc1F

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.73
LMNA P02545 6/20 0.73
SMN1; SMN2 Q16637 3/20 0.73
POLB P06746 2/20 0.73
NPSR1 Q6W5P4 2/20 0.73
GALR2 O43603 1/20 0.73
MITF O75030 1/20 0.73
HSP90AA1 P07900 1/20 0.73
HPGD P15428 1/20 0.73
XBP1 P17861 1/20 0.73
CCR6 P51684 1/20 0.73
KMT2A Q03164 1/20 0.62
KDM4E B2RXH2 2/20 0.51
CHEK1 O14757 1/20 0.48
DAPK3 O43293 1/20 0.48
PRKD3 O94806 1/20 0.48
MET P08581 1/20 0.48
PDGFRA P16234 1/20 0.48
FLT1 P17948 1/20 0.48
LTK P29376 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL670956 0.87 ALDH1A1 (0.57) ALDH1A1LMNASMN1; SMN2POLBNPSR1
SCHEMBL9944758 0.86 ALDH1A1 (0.56) ALDH1A1LMNASMN1; SMN2POLBNPSR1
SCHEMBL1725104 0.84 ALDH1A1 (0.71) ALDH1A1LMNASMN1; SMN2POLBNPSR1
SCHEMBL670959 0.83 ALDH1A1 (0.57) ALDH1A1LMNASMN1; SMN2POLBNPSR1
SCHEMBL29405447 0.83 NPSR1 (0.50) ALDH1A1LMNASMN1; SMN2POLBNPSR1
SCHEMBL9898390 0.82 ALDH1A1 (0.55) ALDH1A1LMNASMN1; SMN2POLBNPSR1
SCHEMBL1969432 0.82 ALDH1A1 (0.64) ALDH1A1LMNASMN1; SMN2POLBNPSR1
SCHEMBL9793657 0.81 SMN1; SMN2 (0.67) ALDH1A1LMNASMN1; SMN2POLBNPSR1
SCHEMBL17930514 0.81 ALDH1A1 (0.56) ALDH1A1LMNASMN1; SMN2POLBNPSR1
SCHEMBL1965597 0.81 NPSR1 (0.49) ALDH1A1LMNASMN1; SMN2POLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916599-B2 1H-benz imidazole-5-carboxamides as anti-inflammatory agents OREXO AB (SE) 2014-12-23 US disclosed
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
EP-2334652-A1 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS Boehringer Ingelheim International GmbH (DE) 2011-06-22 EP disclosed
WO-2010034796-A1 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents MAPRE2, MAPRE1, H1-4 ALDH1A1 1202/4885LMNA 2823/4885SMN1; SMN2 3446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.